

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)



(10) International Publication Number
WO 2021/159015 A1

(51) International Patent Classification:

C07D 213/36 (2006.01) C07D 295/073 (2006.01)
C07C 275/28 (2006.01) C07D 305/08 (2006.01)
A61P 3/00 (2006.01) C07D 309/14 (2006.01)
A61P 25/16 (2006.01) C07D 331/04 (2006.01)
A61P 29/00 (2006.01) C07D 333/08 (2006.01)
A61P 35/00 (2006.01) C07D 335/02 (2006.01)
C07D 205/04 (2006.01) C07D 491/22 (2006.01)
C07D 207/16 (2006.01) A61K 31/17 (2006.01)
C07D 213/81 (2006.01) A61K 31/4422 (2006.01)
C07D 241/12 (2006.01)

(21) International Application Number:

PCT/US2021/016948

(22) International Filing Date:

05 February 2021 (05.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/971,838 07 February 2020 (07.02.2020) US

(71) Applicant: CYTOKINETICS, INC. [US/US]; 280 East Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors: ROMERO, Antonio; 1309 Newbridge Ave, San Mateo, California 94401 (US). CHANDRA, Aroop; 555 Miller Ave, South San Francisco, California 94080 (US). EVANS, Christopher Edward; 668 Hickey Blvd, Apt 3, Pacifica, California 94044 (US). SHEN, Minxing; 2000 Crystal Springs Road, Apt 321, San Bruno, California 94066 (US).

(74) Agent: MCCRUDDEN, Garreth et al.; 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NAMPT MODULATORS



(II)

(57) Abstract: Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

WO 2021/159015 A1